Acute Lung Injury Market Size, Share, Growth Analysis 2032
Acute Lung Injury Market Size and Forecast (2025 - 2032), By Cause (Sepsis, Pneumonia, Inhalation Injury, Near Drowning, Others), By Diagnosis (Chest X-ray, CT Scan, Arterial Blood Gas Test, Others), By Treatment (Mechanical Ventilation, Fluid Management, Pharmacological Treatment, Others), By End User (Hospitals, Speciality Clinics, Research Institutes), and Geography.
Market Overview:
The global acute lung injury market is expected to reach a high CAGR of 3.9% over the Forecast Period 2025-2032. The market will grow from USD XX billion in 2024 to USD YY billion by 2032. North America now dominates the market, accounting for the vast majority of worldwide sales. Key metrics include the rising prevalence of acute respiratory distress syndrome (ARDS), advances in critical care medicine, and increased awareness of the importance of early detection and treatment of acute lung injuries.
The acute lung injury market is growing steadily, owing to rising respiratory disease prevalence, improved healthcare infrastructure, and continued research and development activities in lung injury therapies. Technological advances in diagnostic tools and therapy modalities are improving patient outcomes and broadening the variety of options for treating acute lung injuries.
Market Dynamics:
Market Trend: Adoption of lung-protective ventilation strategies and personalised medicine approaches
The acute lung injury market is experiencing a considerable shift towards the use of lung-protective ventilation methods and personalised medicine approaches. These sophisticated therapeutic approaches seek to reduce ventilator-induced lung injury while tailoring therapy to individual patient features. Lung-protective ventilation strategies, such as reduced tidal volume ventilation and appropriate positive end-expiratory pressure (PEEP) settings, are becoming increasingly used in intensive care units around the world. For example, a meta-analysis published in the Journal of Intensive Care Medicine found that lung-protective ventilation strategies reduced mortality in ARDS patients by 20–25% when compared to standard ventilation approaches. Personalised medicine approaches, which use genetic profiling and biomarker analysis, enable more focused therapy for acute lung injury patients. The expanding awareness of the heterogeneity of acute lung injury, as well as the need for more effective, patient-specific therapies, are driving this trend. Major pharmaceutical and biotechnology companies are investing in research to uncover novel biomarkers and create tailored therapeutics, resulting in a new generation of treatments with higher efficacy and fewer adverse effects.
Market Driver: Increasing incidence of acute respiratory distress syndrome (ARDS) and sepsis-related lung injuries
The increasing prevalence of acute respiratory distress syndrome (ARDS) and sepsis-related lung injuries is a major driver of the acute lung injury market. According to the World Health Organisation, ARDS accounts for 10% of all critical care unit admissions worldwide, with fatality rates ranging from 30% to 50%. The COVID-19 pandemic has underlined the necessity of managing acute lung injury, with a significant proportion of severe COVID-19 cases progressing to ARDS. According to a Lancet Respiratory Medicine study, the incidence of ARDS in hospitalised COVID-19 patients was around 30%, emphasising the need for better therapies. Additionally, sepsis, a significant cause of acute lung injury, affects over 30 million individuals worldwide each year, according to the Global Sepsis Alliance. Demand for enhanced acute lung damage treatments is increasing as people become more aware of the need for early detection and therapy of sepsis. Furthermore, the ageing population and rising frequency of chronic respiratory disorders are driving up the number of acute lung injuries. According to an American Lung Association report, ARDS cases in the United States grew by 15% between 2018 and 2023, owing in part to an increasing geriatric population.
Market Restraint: Limited efficacy of current pharmacological treatments and high cost of advanced therapies
Despite rising demand for acute lung injury treatments, the limited efficacy of current pharmacological approaches and the high cost of newer therapies impede market expansion. Many pharmacological therapies for acute lung injury, including corticosteroids and inhaled nitric oxide, have had variable outcomes in clinical trials, raising questions regarding their overall efficacy. Furthermore, new advanced therapies, such as extracorporeal membrane oxygenation (ECMO) for severe instances, have high prices. According to research in the Journal of Critical Care, the average cost of ECMO treatment for ARDS patients might surpass $150,000 per case, making it difficult to get in resource-constrained settings. The high expense of intensive care and specialised equipment for treating acute lung injuries can put a substantial strain on healthcare systems and individuals, potentially limiting access to optimal care in some areas.
Segment Overview:
Mechanical ventilation dominates the treatment segment, driven by its critical role in managing acute respiratory failure associated with acute lung injury.
The mechanical ventilation sector dominates the acute lung injury treatment market. Mechanical ventilation is a critical component of supportive therapy for patients with acute lung injury and ARDS, providing necessary respiratory support to sustain oxygenation and ventilation. Mechanical ventilation's broad use in intensive care units for acute respiratory failure has propelled it to the forefront of the treatment landscape.
Recent developments in mechanical ventilation technology have strengthened its market dominance. For example, the introduction of adaptive support ventilation modes and automated weaning protocols has enhanced patient-ventilator synchronisation and may shorten the length of mechanical breathing. A multicenter study published in the American Journal of Respiratory and Critical Care Medicine found that using advanced ventilation modes resulted in a 20% reduction in ventilator days and a 15% drop in ICU length of stay for ARDS patients.
Sepsis-induced acute lung damage is driving significant growth in the mechanical ventilation industry. According to the Society of Critical Care Medicine, sepsis is the most common cause of ARDS, accounting for roughly 40% of cases. The complex nature of sepsis-induced lung injury frequently demands prolonged mechanical ventilation support, which contributes to increased use of advanced ventilator systems in this patient group.
Regional Outlook:
North America leads the global acute lung injury market, driven by advanced healthcare infrastructure and high investment in critical care research and development.
North America currently dominates the worldwide acute lung injury market, accounting for the vast majority of revenue. This supremacy is due to a number of factors, including the region's well-established healthcare system, high healthcare spending, and a significant emphasis on critical care research and innovation.
The United States, in particular, makes a significant contribution to the region's market leadership. According to the National Heart, Lung, and Blood Institute, ARDS affects around 200,000 Americans each year, with a death rate of almost 40%. The country's extensive network of academic medical centres and research institutions has resulted in substantial advances in acute lung damage therapy. According to the American Thoracic Society, US institutions led more than 60% of global clinical studies for ARDS treatments between 2018 and 2023.
Recent developments in the North American market have strengthened its position. For example, the FDA's approval of numerous novel respiratory support devices in critical care, such as sophisticated extracorporeal CO2 removal systems, has increased therapy choices for patients with severe acute lung injury. According to a Society of Critical Care Medicine survey, 75% of academic medical centres in the United States have incorporated at least one novel technology for ARDS management during the last three years.
According to a New England Journal of Medicine study, implementing standardised ARDS management guidelines in US hospitals resulted in a 25% reduction in fatality rates over a five-year period. Furthermore, the healthcare The Cost and Utilisation Project reported that the overall yearly cost of ARDS-related hospitalisations in the United States will approach $5 billion by 2023, underscoring the region's enormous economic effect and market potential.
The Canadian market has also played an important role in the region's expansion, with the Canadian Critical Care Trials Group reporting a 30% rise in enrolment for acute lung injury clinical trials over the last five years. The country's universal healthcare system and emphasis on evidence-based medicine have been critical in advancing acute lung injury research and treatment techniques.
Competitive Intelligence:
The acute lung injury market is characterised by fierce competition among prominent competitors, with an emphasis on discovering novel medicines and enhancing supportive care technology. Leading pharmaceutical companies and medical device manufacturers are making significant investments in R&D to address unmet requirements in acute lung injury care.
Pfizer Inc. has a considerable market share due to its range of critical care drugs and continuous development into novel anti-inflammatory therapies for ARDS. In its 2023 financial report, the business stated that its hospital products division, which includes treatments for acute lung injury, grew 12% year on year. GlaxoSmithKline plc follows closely, with its respiratory portfolio and pipeline prospects for acute lung damage gaining traction in clinical trials.
Medtronic plc has strengthened its position in critical care settings by providing advanced ventilator systems and patient monitoring solutions. The company's respiratory and monitoring solutions sector, which includes items used in acute lung injury management, saw a 10% sales rise in the most recent fiscal year.
Drägerwerk AG & Co. KGaA has focused on developing integrated solutions for respiratory care and critical care monitoring to meet the complicated needs of acute lung damage patients. In 2023, the company claimed an 8% increase in sales of its intensive care and ventilation solutions.
ALung Technologies, Inc. has increased market share with their unique extracorporeal CO2 removal system, which is intended to offer additional lung support to patients with acute respiratory failure. The business reported a 25% rise in device placements in 2023, notably in centres that treat severe ARDS cases.
Recent industry changes, such as a major medical technology company acquiring Vapotherm, Inc. in 2022, have transformed the respiratory support market's competitive environment. This consolidation trend is likely to continue, potentially leading to increased market concentration and R&D capacity.
Looking ahead, prominent competitors are focussing on growing their position in emerging areas, particularly Asia-Pacific and Latin America, where acute respiratory illnesses are prevalent and healthcare infrastructure is fast increasing. Furthermore, collaborations with academic institutions and research organisations to perform large-scale clinical studies and develop biomarker-guided medicines are becoming increasingly vital for preserving a competitive edge in the acute lung injury sector.
Analyst Opinion:
Advances in precision medicine, biomarker identification, and novel therapeutic techniques will drive significant growth and innovation in the acute lung injury industry in the coming years. The transition to more targeted therapies, as well as the incorporation of artificial intelligence into critical care decision-making, are predicted to transform the acute lung injury management landscape.
Cell-based therapies, particularly mesenchymal stem cell treatments for acute lung injury, are an emerging trend to keep an eye on. While still in clinical trials, these medicines show promise in reducing inflammation and encouraging lung healing. Early phase studies have yielded positive results, with some trials suggesting a 30-40% increase in oxygenation metrics and perhaps fewer ventilator days for ARDS patients treated with mesenchymal stem cells.
Another area of innovation is the research of inhaled medicines for targeted drug delivery to the lungs. Nanoparticle-based formulations and nebulised drugs are being studied for their ability to increase treatment efficacy while reducing systemic side effects. Preliminary research suggests that inhaled anticoagulants and anti-inflammatory medications may minimise ventilation-perfusion mismatch and enhance outcomes in acute lung injury patients.
Major Players:
-
Pfizer Inc.
-
GlaxoSmithKline plc
-
Medtronic plc
-
Drägerwerk AG & Co. KGaA
-
ALung Technologies, Inc.
-
Getinge AB
-
Hamilton Medical AG
-
Xenios AG (Fresenius Medical Care)
-
Philips Healthcare
-
Fisher & Paykel Healthcare Limited
Key Developments:
-
In November 2024, Pfizer Inc. reported promising phase 3 findings for their novel anti-inflammatory biologic in ARDS patients, exhibiting a 20% reduction in 28-day mortality relative to conventional therapy.
-
In September 2024, Medtronic plc unveiled an AI-powered ventilator system with automated lung-protective methods, promising to optimise ventilation settings and reduce the risk of ventilator-induced lung injury.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Pfizer Inc.
5.2. GlaxoSmithKline plc
5.3. Medtronic plc
5.4. Drägerwerk AG & Co. KGaA
5.5. ALung Technologies, Inc.
5.6. Getinge AB
5.7. Hamilton Medical AG
5.8. Xenios AG (Fresenius Medical Care)
5.9. Philips Healthcare
5.10. Fisher & Paykel Healthcare Limited (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Adoption of lung-protective ventilation strategies and personalised medicine approaches
6.1.2. Development of cell-based therapies, particularly mesenchymal stem cell treatments
6.1.3. Exploration of inhaled therapies for targeted drug delivery to the lungs
6.2. Market Drivers
6.2.1. Increasing incidence of acute respiratory distress syndrome (ARDS) and sepsis-related lung injuries
6.2.2. Advancements in critical care medicine and respiratory support technologies
6.2.3. Growing awareness about early diagnosis and treatment of acute lung injuries
6.3. Market Restraints
6.3.1. Limited efficacy of current pharmacological treatments and high cost of advanced therapies
6.3.2. Challenges in conducting large-scale clinical trials for acute lung injury treatments
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY CAUSE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
7.1. Sepsis
7.1.1. Direct Pulmonary Sepsis
7.1.2. Indirect Pulmonary Sepsis
7.2. Pneumonia
7.2.1. Community-acquired pneumonia
7.2.2. Hospital-acquired pneumonia
7.3. Inhalation Injury
7.3.1. Smoke Inhalation
7.3.2. Chemical Inhalation
7.4. Near Drowning
7.5. Others
7.5.1. Trauma
7.5.2. Pancreatitis
8. BY DIAGNOSIS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
8.1. Chest X-ray
8.2. CT Scan
8.2.1. High-Resolution CT
8.2.2. Low-Dose CT
8.3. Arterial Blood Gas Test
8.4. Others
8.4.1. Lung Ultrasound
8.4.2. Bronchoscopy
9. BY TREATMENT (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
9.1. Mechanical Ventilation
9.1.1. Invasive ventilation
9.1.2. Non-invasive Ventilation
9.2. Fluid Management
9.3. Pharmacological Treatment
9.3.1. Corticosteroids
9.3.2. Antibiotics
9.3.3. Others
9.4. Others
9.4.1. Extracorporeal Membrane Oxygenation (ECMO)
9.4.2. Prone Positioning
10. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
10.1. Hospitals
10.1.1. Intensive Care Units
10.1.2. Emergency Departments
10.2. Speciality Clinics
10.3. Research Institutes
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH (%) -- 2025-2032.
By Cause:
-
Sepsis
-
Pneumonia
-
Inhalation Injury
-
Near Drowning
-
Others
By Diagnosis:
-
Chest X-ray
-
CT Scan
-
Arterial Blood Gas Test
-
Others
By Treatment:
-
Mechanical Ventilation
-
Fluid Management
-
Pharmacological Treatment
-
Others
By End User:
-
Hospitals
-
Speciality Clinics
-
Research Institutes
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511